Glenmark Pharmaceuticals
-
Glenmark, Ichnos to accelerate innovation in cancer treatment
The alliance brings together the drug innovation capabilities of Glenmark and Ichnos to develop cutting‐edge therapies for the treatment of…
Read More » -
Jiangsu Alphamab Biopharmaceuticals, 3D Medicines (Beijing), Glenmark in licensing agreement
Glenmark will be responsible for further developing, registering and commercialising Envafolimab in India, Asia Pacific, Middle East and Africa, Russia,…
Read More » -
Glenmark’s La Shield wins Best Consumer Healthcare Digital Marketing Campaign Award
The science-backed, information-centric approach has set new standards in consumer awareness and brand adoption Glenmark Pharmaceuticals announced that its skincare…
Read More » -
Glenmark Pharma launches triple-drug FDC for Type 2 diabetes in India
Zita DM helps improve glycemic control in adult patients with high HbA1c and/or other co-morbidities Glenmark Pharmaceuticals has launched the…
Read More » -
Glenmark Pharma, OMRON Healthcare India team up to combat hypertension
Aims to reach out to around 92,000 Healthcare Professionals (HCPs) and around ten crore Indians in one year Glenmark Pharmaceuticals…
Read More » -
Glenmark Pharmaceuticals hosts drug discovery workshop for Sion Hospital students
The event had over 3000 MBBS student delegates from across the country and around the world Glenmark Pharmaceuticals, an integrated,…
Read More » -
Glenmark Pharma becomes part of Science Based Targets initiative
Sets Green House Gas emission targets for FY 2035 Glenmark Pharmaceuticals has joined the esteemed Science Based Targets initiative (SBTi)…
Read More » -
Glenmark receives US FDA nod for GRC 54276 to treat advanced solid tumours and lymphomas
GRC 54276 is an orally available, small-molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor Glenmark Specialty, the subsidiary of Glenmark Pharmaceuticals,…
Read More » -
Glenmark in exclusive distribution agreement with Cediprof
Glenmark expects to commence distribution of the product in the US during the second half of 2023 Glenmark Pharmaceuticals, USA…
Read More » -
Glenmark launches AKYNZEO IV for prevention of chemotherapy-induced nausea and vomiting
AKYNZEO IV, a fixed-dose combination of fosnetupitant (235mg) and palonosetron(0.25mg), will be available as a single-dose, ready-to-dilute IV injection Glenmark…
Read More »